President Donald Trump is once again putting America first—this time targeting the powerful pharmaceutical industry. As part of his America First trade agenda, Trump is preparing to slap tariffs on imported pharmaceutical products, ending the industry’s longtime free pass. Global drugmakers, fearing the financial impact, are now lobbying his administration to gradually introduce the 25% tariffs he’s promised—hoping to soften the blow and buy time to shift production.
Sources close to the matter say Trump isn’t backing down. While the exact timing and scope of the pharma tariffs may not be announced immediately, it’s clear the president is determined to bring drug manufacturing back home. Trump’s push comes after decades of American dependence on foreign supply chains for life-saving medications—a risk he’s determined to eliminate.
The pharmaceutical giants—many of which manufacture key drug ingredients in Europe and Asia—are pushing for a phased approach, arguing that building U.S. production takes time and money. They’ve met with Trump officials, claiming it could take up to a decade and $2 billion to shift operations stateside.
But the Trump administration knows the excuses. Some companies—like Johnson & Johnson, Eli Lilly, AstraZeneca, and GSK—are already investing billions in U.S. plants. That’s the kind of action Trump wants. He’s making it clear: no more excuses or free rides.
Critics claim tariffs might cause shortages, but Trump knows the real crisis is America’s reliance on foreign nations. He’s ready to protect American jobs, secure our medicine supply, and hold Big Pharma accountable.
As Wednesday’s expected tariff announcement nears, one thing is clear—President Trump is taking on Big Pharma with the same tenacity he’s shown with China, Mexico, and beyond. America comes first. Always.
